60
Participants
Start Date
July 1, 2023
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
Psilocybin 25 mg
The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.
Risperidone 1 MG
The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.
Placebo
The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
RECRUITING
Centre for Addiction and Mental Health, Toronto
Centre for Addiction and Mental Health
OTHER